| Bulk0001 | Keith Kerstann(2007) | Metastatic Melanoma | SKCM | Adoptive Cell Therapy | response/non-response | 12/16 | tumor infiltrating lymphocytes | GSE6592 |
| Bulk0002 | Irvin DK.PLoS One(2010) | Gliomas | GBMLGG | Cancer Vaccine | treatment/non-treatment | 6/10 | Brain | GSE11100 |
| Bulk0003 | Biernacki MA.Cancer Res(2010) | chronic myelogenous leukemia | CML | Adoptive Cell Therapy | treatment/non-treatment | 2/2 | Serum | GSE11565 |
| Bulk0004 | Biernacki MA.Cancer Res(2010) | chronic myelogenous leukemia | CML | Adoptive Cell Therapy | treatment/non-treatment | 2/1 | Serum | GSE11565 |
| Bulk0005 | Kim YJ.Clin Cancer Res(2010) | Bladder cancers | BLCA | Cancer Vaccine | response/non-response | 26/22 | Bladder | GSE19423 |
| Bulk0006 | Rafael Carretero(2011) | Metastatic Melanoma | SKCM | Cancer Vaccine | response/non-response;treatment/non-treatment | 6/4;5/5 | Skin | GSE26383 |
| Bulk0007 | Wolf B.PLoS One(2012) | renal cell carcinoma | KIRC | Cancer Vaccine | treatment/non-treatment | 13/17 | Periphereal blood lymphocytes | GSE34465 |
| Bulk0008 | Ulloa-Montoya F. J Clin Oncol(2013) | Melanoma | SKCM | Cancer Vaccine | response/non-response | 22/34 | Skin | GSE35640 |
| Bulk0009 | Kwek SS.J Immunol(2012) | prostate cancer | PRAD | Immune Checkpoint Therapy | response/non-response;treatment/non-treatment | 10/12;11/11 | Serum | GSE39688 |
| Bulk0010 | Florcken A.Int J Cancer(2015) | advanced renal cell cancer | KIRC | Cancer Vaccine | treatment/non-treatment | 9/9 | PMBCs | GSE51490 |
| Bulk0011 | Newman AM.Nat Methods(2015) | follicular lymphoma | DLBC | Immunostimulant OR Targeting Therapy | treatment/non-treatment | 1/3 | PMBCs | GSE65135 |
| Bulk0012 | Ascierto ML.Cancer Immunol Res(2016) | Renal Cell Carcinoma | KIRC | Immune Checkpoint Therapy | response/non-response | 4/7 | RCC Primary tumor | GSE67501 |
| Bulk0013 | Hugo W.Cell (2016) | Metastatic Melanoma | SKCM | Immune Checkpoint Therapy | response/non-response | 15/13 | Skin | GSE78220 |
| Bulk0014 | Ascierto ML.Clin Cancer Res(2017) | melanoma skin metastasis | SKCM | Immune Checkpoint Therapy | response/non-response | 6/4 | Skin | GSE79691 |
| Bulk0015 | Francesco Maria Marincola(2017) | metastatic melanoma | SKCM | Cancer Vaccine | treatment/non-treatment | 14/7 | Skin | GSE79741 |
| Bulk0016 | Mauldin IS.Cancer Immunol Immunother(2016) | metastatic melanoma | SKCM | Cancer Vaccine | treatment/non-treatment | 8/3 | Skin | GSE80028 |
| Bulk0017 | Riaz N.Cell(2017) | melanoma;non-small cell lung cancer | SKCM;NSCLC | Immune Checkpoint Therapy | response/non-response;treatment/non-treatment | 23/82;58/51 | Skin | GSE91061 |
| Bulk0018 | Lauss M.Nat Commun (2017) | melanoma | SKCM | Adoptive Cell Therapy | response/non-response | 10/15 | Skin | GSE100797 |
| Bulk0019 | Garcia-Salum T.Oncotarget(2018) | Melanoma | SKCM | Adoptive Cell Therapy | treatment/non-treatment | 39/8 | Blood | GSE106128 |
| Bulk0020 | Auslander N.Nat Med(2018) | metastatic melanoma | SKCM | Immune Checkpoint Therapy | response/non-response | 3/34 | Skin | GSE115821 |
| Bulk0021 | Vujanovic L.Front Immunol(2019) | Melanoma | SKCM | Cancer Vaccine | response/non-response;treatment/non-treatment | 5/36;21/20 | Skin | GSE124574 |
| Bulk0022 | Cho JW.Exp Mol Med(2020) | non-small cell lung cancer | NSCLC | Immune Checkpoint Therapy | response/non-response | 5/11 | NSCLC | GSE126044 |
| Bulk0023 | Jung H.Nat Commun(2019) | non-small cell lung carcinoma | NSCLC | Immune Checkpoint Therapy | response/non-response | 6/21 | Lung | GSE135222 |
| Bulk0024 | Hwang S.Sci Rep(2020) | non-small cell lung carcinoma | NSCLC | Immune Checkpoint Therapy | response/non-response | 9/12 | Lung | GSE136961 |
| Bulk0025 | Quintela-Fandino M.Breast Cancer Res (2020) | HER2-negative advanced breast cancer | BRCA | Immune Checkpoint Therapy | response/non-response | 3/3 | Breast tumor | GSE139050 |
| Bulk0026 | Middleton MR.Clin Cancer Res(2020) | Metastatic Melanoma | SKCM | Immunostimulant OR Targeting Therapy | response/non-response;treatment/non-treatment | 5/20;16/9 | Skin | GSE139566 |
| Bulk0027 | Hatae R.JCI Insight (2020) | Non-small cell lung cancer | NSCLC | Immune Checkpoint Therapy | treatment/non-treatment | 33/41 | Peripheral blood | GSE141479 |
| Bulk0028 | Lim J(2020) | GBM | GBM | Adoptive Cell Therapy | response/non-response | 5/7 | Glioblastoma tumor | GSE142693 |
| Bulk0029 | Baruch EN.Science (2021) | melanoma | SKCM | Immune Checkpoint Therapy | response/non-response;treatment/non-treatment | 9/9 | Sigmoid colon;Remote tumor metastasis | GSE162436 |
| Bulk0030 | Lee JS.Cell (2021) | Lung cancer | NSCLC | Immunotherapy | response/non-response | 7/15 | Lung | GSE166449 |
| Bulk0031 | van den Ende T.Clin Cancer Res(2021) | esophageal adenocarcinoma | ESAD | Immune Checkpoint Therapy | response/non-response | 23/48 | Esophageal adenocarcinoma | GSE165252 |
| Bulk0032 | Monica Martinez-Fernandez(2018) | bladder cancer | BLCA | Immune Checkpoint Therapy | response/non-response | 6/5 | Bladder | GSE111636 |
| Bulk0033 | David T Ting(2021) | microsatellite stable colorectal;pancreatic cancer | COCA;PAAD | Immune Checkpoint Therapy | treatment/non-treatment | 11/43 | Metastatic tumor | GSE179351 |
| Bulk0034 | Loughran TP Jr.Leukemia (2015) | Large Granular Lymphocyte leukemia | LGLL | Immunosuppressive Therapy | response/non-response | 19/18 | PBMC | GSE42664 |
| Bulk0035 | Rajkumar Balakrishnan(2020) | chronic lymphocytic leukemia | CLL | Immune Checkpoint Therapy | response/non-response | 30/32 | CD3+ T cells | GSE148476 |
